A mother with a terminal illness has successfully raised over £50,000 from public donations after making an emotional plea for the NHS to cover the cost of the life-prolonging drug Enhertu. Jess Duggan, 44, expressed gratitude for the overwhelming support she received, describing it as “astonishing.” Following the crowdfunding efforts to afford the medication privately, she has undergone her first treatment and commemorated her daughter’s 16th birthday, eagerly hoping to witness her son’s 13th celebration in September.
The situation highlights the denial of Enhertu to Jess and numerous other women battling breast cancer in England, Wales, and Northern Ireland, while it remains accessible at no cost in Scotland and 26 other European nations. Jess views the funds raised for her treatment as a reflection of public discontent with this “inhumane” stance.
An opinion poll by Breast Cancer Now unveiled that 82% of UK adults believe the life-extending drug should be accessible through the NHS for those in need. Jess, who is fighting breast cancer that has metastasized to her brain and liver, recently had the painful task of informing her children that she has only six weeks left to live. Expressing their frustration over the unavailability of the drug on the NHS, Jess shared her children’s sorrow at being deprived of their mother.
Despite her challenges, Jess, from Lewes, is courageously advocating for the NHS to cover the cost of the drug. She expressed gratitude for the overwhelming response to the crowdfunding campaign, emphasizing the kindness and generosity of strangers. Urging the new Health Secretary Yvette Cooper to prioritize funding for Enhertu, she highlighted the current rejection of the drug due to its high cost.
Given a prognosis of six weeks in early July, Jess made the difficult decision to seek public assistance to finance the drug, known to extend life by six months. She acknowledged the difficulty in asking for financial help but expressed deep gratitude for the support received. With funds totaling £50,000, Jess has covered the cost of five doses of the drug, including associated medical expenses.
Reflecting on her treatment journey, Jess remains optimistic about the effectiveness of Enhertu, contrasting it with the limited options offered by traditional chemotherapy. She emphasized the challenges faced by patients in accessing the drug privately and acknowledged the dedicated individuals who facilitated her fundraising efforts.
While celebrating her daughter’s recent milestone, Jess lamented the lack of access to Enhertu that could have altered her cancer progression significantly. She emphasized the uncertainty surrounding her future treatments and financial decisions, calling attention to the urgency of making the drug more widely available.
The ongoing unavailability of Enhertu for metastatic breast cancer patients like Jess has triggered widespread concern, with advocacy groups and petitions demanding immediate action to provide access to the life-prolonging medication. The National Institute for Health and Care Excellence (NICE) cited cost-effectiveness as a key factor in its previous decision to reject Enhertu for NHS use, but discussions are underway to explore commercial agreements that could make the drug more accessible.
In response to the growing calls for action, health authorities have expressed condolences to individuals affected by breast cancer and assured ongoing discussions with drug manufacturers to address the accessibility of Enhertu. The situation underscores the pressing need to expedite decisions that can significantly impact the lives of those battling metastatic breast cancer.